SOUTH SAN FRANCISCO, Calif., October 21, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. ALGSa clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced seven upcoming poster presentations at the Liver Meeting® (November 4-8, 2022), the is hosted by the American Association for the Study of Liver Disease (AASLD).
All posters covering drug candidates targeting chronic hepatitis B (CHB) and nonalcoholic steatohepatitis (NASH) will be available on the Aligos website at Scientific presentations & conferences after the end of the conference.
“The 2022 Liver Meeting® will showcase the breadth and depth of Aligos’ portfolio of potential treatments for CHB and the continued advances in our NASH program,” said Lawrence Blatt, Ph.D., MBA, Aligos CEO and Chairman of the Board. “We are pleased to provide an update at the conference on our clinical-stage drug candidates, specifically our class 2 capsid assembly modulator (CAM) for CHB, ALG-000184, which continues to show best-in-class declines in a variety We will also present preclinical data for ALG-125755, our siRNA drug candidate developed to lower HBsAg and currently being administered in Phase 1 healthy volunteers, showing a well-tolerated safety profile and reductions in various lipid levels that we observed after hyperlipidemic patients have received multiple doses of our thyroid hormone beta-agonist ALG-055009.”
dr Blatt continued, “We are also pleased to share preclinical results for two early-stage CHB programs, including a second class of small molecule CAMs and two modalities of PD-L1 inhibitors.”
Chronic hepatitis B
Capsid Assembly Modulator-2 (CAM-2)
Title: Safety, Pharmacokinetics (PK), and Antiviral Activity of Capsid Assembly Modulator (CAM) ALG-000184 in Patients With HBeAg-Positive Chronic…
